China has cleared Akeso’s AK157D1 for Phase 1 testing in advanced solid tumors, adding a DXd-class B7-H3 programme to a target already attracting late-stage ADC competition.
Akeso and INOVIO test cadonilimab plus INO-5412 in the INSIGhT glioblastoma trial. Explore what this immunotherapy strategy could mean for GBM research.
Cadonilimab outperforms PD-1 inhibitors in PD-L1-low gastric cancer patients. Find out what this means for global immunotherapy standards.
Akeso Inc. has secured clearance from the United States Food and Drug Administration to initiate COMPASSION-37, a global Phase III trial evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody, as part of a first-line treatment regimen for HER2-negative, unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma. The randomized, multicenter trial will compare cadonilimab plus chemotherapy against